Close

UCB, ConfometRx sign drug discovery research deal

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Small Molecule API Market Growth Analysis and Future Trends

Small Molecule API Market Size, Share, and Growth Analysis The...

Reviving Old Drugs with Specialty Intermediates in Europe

Drug development in the European pharmaceutical industry is undergoing...

Specialty Chemicals Solubility Enhances Drug Formulations

The need to improve the effectiveness, safety, and accessibility...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Belgium-based biopharmaceutical company UCB has signed a research deal with ConfometRx for the discovery of new drugs.

Under the deal, UCB and ConfometRx will leverage structural biology to gain insight into G-protein coupled receptor (GPCR) modulation towards the design of differentiated drugs.

GPCRs, which are signaling proteins in the human genome, are involved in virtually regulating all physiological processes.

The terms of the agreement include an up-front payment, research funding and success-based milestones.

ConfometRx CEO Tong Sun Kobilka said the company is delighted to work with UCB’s central nervous system research group to enhance the drug development activities.

“With over 20 years of experience working in the coupled receptor field and our unique technological approach, we believe that we can bring significant value to UCB’s novel drug development process,” Kobilka added. “We look forward to working closely with UCB’s R&D teams.”

 

 

Latest stories

Related stories

Small Molecule API Market Growth Analysis and Future Trends

Small Molecule API Market Size, Share, and Growth Analysis The...

Reviving Old Drugs with Specialty Intermediates in Europe

Drug development in the European pharmaceutical industry is undergoing...

Specialty Chemicals Solubility Enhances Drug Formulations

The need to improve the effectiveness, safety, and accessibility...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back